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Background: Dyslipidemia and type 2 diabetes are two of the most significant risk factors for the
development of cardiovascular disease. Measurement of lipoprotein subclasses provides important information about derangements in lipid metabolism and helps refine cardiovascular risk
assessment. Exenatide, a glucagon-like peptide 1 receptor agonist, improved glycemic control,
obesity, hypertension, and dyslipidemia in patients with type 2 diabetes in clinical trials.
Methods: In the DURATION-1 trial, patients with type 2 diabetes were treated with exenatide
once weekly or twice daily for 30 weeks. This post hoc analysis evaluated the impact of
exenatide on lipoprotein subclasses in 211 DURATION-1 patients using vertical auto profile
methodology and the Statistical Package for the Social Sciences general linear model adjusted
for glycosylated hemoglobin (HbA1c) and weight.
Results: Baseline lipids and high sensitivity C-reactive protein were normal overall based on the
standard lipid panel. Once-weekly exenatide reduced apolipoprotein B and the apolipoprotein B
to apolipoprotein A1 ratio (P , 0.05), independent of glycemic improvement and weight loss.
A significant shift in lipoprotein pattern away from small, dense low-density lipoprotein-4
cholesterol was also observed (P , 0.05). Exenatide once weekly increased high-density
lipoprotein-2 cholesterol, even after adjustment for changes in HbA1c and weight (P , 0.05).
Triglycerides, very low-density lipoprotein cholesterol, and high sensitivity C-reactive protein
were reduced with both the once-weekly and twice-daily exenatide regimens (P , 0.05).
Conclusion: In this post hoc analysis, exenatide significantly improved a number of cardiovascular risk markers. Continuous exenatide exposure with exenatide once weekly elicited a greater
response than did immediate-release exenatide twice daily, generally independent of glycemic
improvement and weight loss. Thus, in addition to improving glycemic control, exenatide induced
favorable changes in lipid and lipoprotein metabolism and decreased systemic inflammation.
Keywords: glucagon-like protein-1 receptor agonist, incretin mimetic, dyslipidemia, type 2
diabetes mellitus
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Dyslipidemia in patients with type 2 diabetes increases the risk of cardiovascular
disease.1–3 In insulin-resistant states, such as type 2 diabetes, there is greater constitutive
mobilization of fatty acids from triglyceride stores in visceral adipose tissue, increased
hepatic secretion of very low-density lipoprotein (VLDL) cholesterol, inhibition of
lipoprotein lipase to some degree, and activation of cholesteryl ester transfer protein.
Given these metabolic disturbances, the typical lipid profile in patients with type 2
diabetes includes elevated triglycerides and VLDL cholesterol, increased numbers of
small, dense low-density lipoprotein (LDL) cholesterol and other atherogenic lipoproteins, and reduced high-density lipoprotein (HDL) cholesterol.2
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Reducing LDL cholesterol is the primary target of dyslipidemia therapy in both primary and secondary prevention.
However, LDL cholesterol incompletely assesses the contribution of all atherogenic lipoproteins, such as VLDL or
intermediate-density lipoprotein (IDL), to cardiovascular
disease risk. Direct measurement of circulating apolipoprotein B concentrations has been proposed as a better method
for assessing this risk because it more accurately reflects the
true burden of all atherogenic lipoproteins.4
Restoration of glycemic control and relieving insulin
resistance promotes reductions in serum triglyceride levels,
primarily by reducing free fatty acid and glucose levels,
both of which fuel hepatic triglyceride production. However,
lowering of glucose rarely results in pronounced improvements in LDL and HDL cholesterol or their subclasses.
Given the increased burden of cardiovascular risk factors in
patients with type 2 diabetes, it is critical to understand how
current antihyperglycemic agents impact these risk factors
and the progression of atherosclerosis, and to incorporate
this knowledge into routine clinical practice. For example,
the InterHeart study reported that smoking, dyslipidemia,
hypertension, abdominal obesity, and diabetes account for
80% of the risk for an acute myocardial infarction,5 and that
the strongest risk predictor is the ratio of apolipoprotein B to
apolipoprotein A1. Also, the Quebec Cardiovascular Study
found that the combination of diabetes, elevated small,
dense LDL cholesterol, and elevated apolipoprotein B
synergistically confer a 20-fold increased risk for cardiovascular events.6 Other studies suggested that high sensitivity
C-reactive protein, a proinflammatory biomarker, helped to
refine risk estimates beyond the measurement of established
Framingham risk factors.7 Nissen et al8 demonstrated that
progression of atherosclerosis is slower when atherogenic
lipoprotein and high sensitivity C-reactive protein levels
are both reduced.
Exenatide is a glucagon-like protein-1 receptor agonist
that has been demonstrated to have multiple glucoregulatory
effects in patients with type 2 diabetes, including glucosedependent enhancement of insulin secretion, suppression of
inappropriately high glucagon secretion, slowing of gastric
emptying, and reduction of food intake, usually accompanied by weight loss.9 Additional effects of exenatide
are under investigation, including improved endothelial
function, reduced systolic blood pressure, decreased oxidative stress and inflammation, and improved myocardial
bioenergetics.10–13 Preliminary investigation with nuclear
magnetic resonance imaging demonstrated an exenatideinduced shift away from small LDL lipoproteins towards
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larger, more buoyant LDL lipoproteins (small LDL cholesterol change from baseline −146 ± 67 nmol/L, P = 0.037;
large LDL cholesterol change from baseline 68 ± 27 nmol/L,
P = 0.017) after 52 weeks of exenatide twice daily, compared
with biphasic insulin aspart, on a background of metformin
and sulfonylurea in patients with type 2 diabetes.14,15
In this post hoc analysis of data from the 30-week
DURATION-1 (Diabetes Therapy Utilization: Researching
Changes in A1c, Weight and Other Factors Through Intervention with Exenatide Once Weekly) clinical trial,16 the effects
of two exenatide formulations (immediate-release exenatide
twice daily and extended-release exenatide once weekly)
on lipoproteins and high sensitivity C-reactive protein were
explored using a validated vertical auto profile ultracentrifuge
methodology.17 This is the first comprehensive lipoprotein
subclass analysis performed for a glucagon-like protein-1
receptor agonist in human patients with type 2 diabetes.

Materials and methods
Details on the DURATION-1 study (clinicaltrials.gov
NCT00308139) have been reported previously.16 In brief,
patients with type 2 diabetes were treated with exenatide 2 mg
once weekly or exenatide 10 µg twice daily for 30 weeks. Of
the 295 intent-to-treat patients in DURATION-1, 211 were
assessed for lipid subclass concentrations at baseline and
week 30 using vertical auto profile technology,17 and constitute the analysis cohort. The vertical auto profile method
involves independent measurements of total cholesterol,
HDL cholesterol, and triglycerides.17 The validated vertical
auto profile technique is an inverted rate zonal, single vertical spin, density gradient ultracentrifugation technique that
simultaneously and directly measures cholesterol concentrations of all five lipoprotein classes (HDL cholesterol, LDL
cholesterol-real [LDL cholesterol without lipoprotein(a)
and IDL cholesterol], VLDL cholesterol, IDL cholesterol,
lipoprotein(a)) and their subclasses.17,18 The vertical auto
profile separates all lipoproteins in three steps: a two-layer
density gradient is prepared with the bottom layer containing
a 1:40 serum dilution with KBr; the gradient is centrifuged at
65,000 rpm for approximately 45–60 minutes; and the layers
are analyzed using a continuous flow cholesterol analyzer.
Output has been validated against standardized reference tests
from the Core Laboratory for Clinical Studies at Washington
University School of Medicine in St Louis, MO, using beta
quantification.19 High sensitivity C-reactive protein was measured using the Multigent CRP Vario™ assay (Ilex Medical
Systems, Petach-Tikva, Israel) and the Architect c8000®
system for quantitative immunoturbidometric determination
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(Abbott Diagnostics, Abbott Park, IL). Data were analyzed
using the Statistical Package for Social Sciences version 17.0
(IBM, Armonk, NY) general linear model-univariate
analysis. Outcome variables of interest at study end were
treated as dependent variables, adjusted for baseline and week
30 change in glycosylated hemoglobin (HbA1c) and weight.
The statistical significance level was set at P , 0.05.

Results
General demographics and baseline values for the total analysis cohort are shown in Table 1. The patients were generally
middle-aged, obese Caucasians with a mean HbA1c of 8.2%.
Approximately two thirds of the cohort were treated with metformin, and more than half with a statin. In the total analysis
cohort, mean baseline lipid concentrations were generally
within the normal range based on the standard lipid panel.1–3
However, as shown below, there was actually a preponderance
of small, dense LDL cholesterol lipoproteins, and the LDL
cholesterol distribution in both treatment groups (exenatide
once weekly or twice daily) was skewed towards the smaller
LDL3 cholesterol and LDL4 cholesterol. On average, the more
buoyant HDL2 cholesterol was below the recommended target
goal1–3 at baseline, with a resulting apolipoprotein B to apolipoprotein A1 ratio above 0.6 (60%). Exenatide treatment for
30 weeks significantly reduced mean HbA1c (exenatide once
weekly −1.6%; exenatide twice daily −1.2%) and body weight
from baseline (exenatide once weekly −3.9 kg; exenatide twice
daily −3.8 kg, Figure 1A and B).
Lipoprotein and apoprotein measurements for the total
cohort are shown in Table 2, and week 30 changes after
adjustment for HbA1c and weight changes are shown in
Figure 1C–H. Exenatide once weekly significantly reduced
triglycerides, apolipoprotein B, the apolipoprotein B to apolipoprotein A1 ratio, LDL4 cholesterol, and VLDL cholesterol
(P , 0.05). Exenatide twice daily reduced triglycerides and
VLDL cholesterol (P , 0.05). The changes in apolipoprotein
A1, LDL cholesterol, LDL1 cholesterol, LDL2 cholesterol,
LDL3 cholesterol, IDL cholesterol, VLDL3 cholesterol,
VLDL1+2 cholesterol, non-HDL cholesterol, remnant lipoproteins, and lipoprotein(a) cholesterol were not significant
with either treatment. Despite no statistically significant
effect on total HDL cholesterol after adjustment for changes
in HbA1c and weight, exenatide once weekly significantly
increased HDL2 cholesterol (P , 0.05), but not HDL3
cholesterol. In contrast, twice-daily treatment with exenatide
resulted in no change in HDL cholesterol subclasses.
Among patients with abnormal baseline lipid values,1–3
exenatide once weekly significantly improved apolipoprotein B,
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Table 1 Demographics and baseline characteristics for the
lipoprotein subclass analysis cohort
Total cohort

Age (years)
Female (%)
Caucasian (%)
Black/African American (%)
Hispanic (%)
Asian (%)
A1c (%)
Body weight (kg)
BMI (kg/m2)
Apolipoprotein A (g/L)
Apolipoprotein B (g/L)
Apolipoprotein B/A1 (%)
Triglycerides (mmol/L)
LDL-C (mmol/L)
LDL1-C (mmol/L)
LDL2-C (mmol/L)
LDL3-C (mmol/L)
LDL4-C (mmol/L)
VLDL-C (mmol/L)
HDL-C (mmol/L)
HDL-2 (mmol/L)
HDL-3 (mmol/L)
Diabetes medications (%)
 None
MET alone
SFU alone
TZD alone
MET + TZD
MET + SFU
TZD + SFU
MET + TZD + SFU
Dyslipidemia medications (%)
Statin
Statin + CAI
 Niacin
Fibrate
CAI
Fish oil

ExQW
n = 106

ExBID
n = 105

56 ± 9
36.8
84.9
4.7
10.4
0
8.2 ± 0.9
101 ± 18
34.8 ± 5.0
1.3 ± 0.2
0.81 ± 0.21
61 ± 15
2.14 ± 1.40
2.16 ± 0.80
0.22 ± 0.17
0.17 ± 0.19
0.75 ± 0.36
0.54 ± 0.29
0.59 ± 0.20
1.04 ± 0.24
0.20 ± 0.09
0.84 ± 0.16

55 ± 10
47.6
73.3
11.4
14.3
1.0
8.2 ± 0.9
104 ± 22
34.9 ± 5.3
1.3 ± 0.2
0.86 ± 0.23
65 ± 17
2.11 ± 1.44
2.42 ± 0.94
0.27 ± 0.19
0.23 ± 0.28
0.82 ± 0.43
0.56 ± 0.29
0.60 ± 0.21
1.06 ± 0.27
0.20 ± 0.09
0.86 ± 0.20

15.2
34.9
2.8
1.9
11.3
29.2
3.8
0.9

10.4
33.3
6.7
14.3
3.8
26.7
2.9
1.9

61.3
7.5
2.8
7.5
8.5
7.5

44.8
5.7
4.8
9.5
4.8
5.7

Note: Values are mean ± SD.
Abbreviations: ApoB, apolipoprotein B; ApoA1, apolipoprotein A1; BMI, body
mass index; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density
lipoprotein cholesterol; VLDL-C, very low-density lipoprotein cholesterol; CAI,
cholesterol absorption inhibitor; MET, metformin; SD, standard deviation; SFU,
sulfonylurea; TZD, thiazolidinedione; A1c, glycosylated hemoglobin; ExQW, exenatide
once weekly; ExBID, exenatide twice daily.

the apolipoprotein B to apolipoprotein A1 ratio, LDL cholesterol, LDL3+4 cholesterol/LDL cholesterol, LDL1+2 cholesterol/LDL cholesterol, triglycerides, VLDL cholesterol,
VLDL3 cholesterol, IDL cholesterol, non-HDL cholesterol,
and remnant lipoproteins (P , 0.05; F
 igure 2A–E). Exenatide
twice daily improved apolipoprotein B, the apolipoprotein B
to apolipoprotein A1 ratio, LDL cholesterol, triglycerides,
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A

B

A1c
BL

8.2

Change from baseline (kg)

−1.0

−1.5

−1.2%

*

Exenatide QW

−1.6%

Exenatide BID

*

−3.8 kg

−0.01
−0.02
−0.03

−0.013

−0.04
−0.05

−0.036

*

−0.06

E
0.08
0.06
0.04
0.02
0.00
−0.02
−0.04
−0.06
−0.08
−0.10
−0.12
−0.14

0.22 0.27

0.17 0.23

0.01

−0.01 −0.01
−0.02
−0.02
−0.05

*

−0.07

LDL1-C

LDL2-C

LDL3-C

LDL4-C

0.05

1.04

1.07

0.20

0.21

0.84

−4

−3.1

*

Triglycerides

0.005

0.02

*

0.013
0.005

0.01
0.00
−0.01
−0.02

−0.002

−0.03
HDL-C

HDL2-C

HDL3-C

VLDL-C

2.1

0.6

0.6

NonHDL-C
2.75

3.03

0.2
0.015

0.0

−0.2

−0.086

−0.4

−0.6

−0.36

−0.34

*

*

−0.33

−0.34

*

*

8

0.032

0.018

2.1

Percentage change in HDL-C subclass

0.86

0.04
0.03

−1.0

−3

H

HDL-C and subclasses
BL

65

−2

BL

0.01

G

61

−1

0.54 0.56

0.02

*
% ApoB/ApoA1

F

0.75 0.82
0.05

LDL-C

*

−5
LDL-C and subclasses

BL 2.16 2.42

−4

BL

Change from baseline (%)

0.86

Change from baseline (mmol/L)

Change from baseline (%)

−3.9 kg

−2

D

ApoB
0.81

BL

Change from baseline (mmol/L)

104

−6

Change from baseline (%)

Change from baseline (%)

−0.5

−2.0

Change from baseline (mmol/L)

101

0

0.0

C

Body weight
BL

8.2

*

7
6
5
4
3
2
1
0
HDL-C

HDL2-C

HDL3-C

Figure 1 Effects of exenatide on glycosylated hemoglobin, body weight, apolipoproteins, and lipoproteins in the total analysis cohort with an overall normal lipid profile at baseline.
Week 30 change data are independent of glycemic improvement and weight loss. (A) Glycosylated hemoglobin. (B) Body weight. (C) Apolipoprotein B. (D) Percentage of
apolipoprotein B/apolipoprotein A1. (E) Low-density lipoprotein cholesterol and its subclasses. (F) Triglycerides, very low-density lipoprotein cholesterol, and non-high-density
lipoprotein cholesterol. (G) High-density lipoprotein cholesterol and its subclasses. (H) Percentage changes in high-density lipoprotein cholesterol and its subclasses. (Panels A
and B) Least squares mean + 95% confidence intervals. *Change from baseline P , 0.0001. (Panels C–G) Adjusted mean + standard error of the mean.
Notes: *Week 30 change from baseline P , 0.05. Once weekly, n = 106, twice daily, n = 105.
Abbreviations: A1c, glycosylated hemoglobin; ApoB, apolipoprotein B; ApoA1, apolipoprotein A1; BID, twice daily; LDL-C, low-density lipoprotein cholesterol; VLDL-C,
very low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; QW, once weekly.

VLDL cholesterol, IDL cholesterol, non-HDL cholesterol,
and remnant lipoproteins (P , 0.05). Because recommended HDL cholesterol concentrations differ by gender
(.1.0 mmol/L in men and .1.3 mmol/L in women),20 these
variables were evaluated separately for men and women.
Results of these analyses show that exenatide once weekly
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significantly improved HDL and HDL2 cholesterol in women,
HDL and HDL3 cholesterol in men, and HDL2/HDL cholesterol in both men and women (P , 0.05); exenatide twice
daily significantly improved HDL3 cholesterol in men and
HDL cholesterol in both men and women (P , 0.05). In
the exenatide once-weekly treatment group, the percentage
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Table 2 Apolipoprotein and lipoprotein change from baseline in
patients with type treated with exenatide for 30 weeks for the
lipoprotein subclass analysis cohort

ApoA1 (g/L)
ApoB (g/L)
ApoB/ApoA1 (%)
Triglycerides
(mmol/L)
LDL-C (mmol/L)
LDL1-C (mmol/L)
LDL2-C (mmol/L)
LDL3-C (mmol/L)
LDL4-C (mmol/L)
IDL-C (mmol/L)
VLDL-C (mmol/L)
VLDL3-C (mmol/L)
VLDL12-C
(mmol/L)
nonHDL-C
(mmol/L)
RLPs (mmol/L)
Lp(a) (mmol/L)
HDL-C (mmol/L)
HDL2-C (mmol/L)
HDL3-C (mmol/L)

ExQW
(n = 106)

ExBID
(n = 105)

0.016 (-0.011, 0.042)
-0.036* (-0.065, -0.008)
-3.1 (-5.0, -1.3)*
-0.361 (-0.566, -0.155)*

-0.001 (-0.028, 0.025)
-0.013 (-0.041, 0.015)
-1.0 (-2.8, 0.9)
-0.339 (-0.546, -0.132)*

-0.073 (-0.192, 0.028)
-0.008 (-0.035, 0.019)
0.024 (-0.008, 0.055)
-0.020 (-0.080, 0.040)
-0.052 (-0.098, -0.006)*
-0.005 (-0.025, 0.015)
-0.327 (-0.360, -0.295)*
-0.007 (-0.022, 0.008)
-0.004 (-0.026, 0.018)

0.009 (-0.111, 0.129)
-0.006 (-0.034, 0.021)
0.012 (-0.019, 0.044)
0.050 (-0.011, 0.110)
-0.015 (-0.061, 0.031)
-0.005 (-0.025, 0.015)
-0.343 (-0.375, -0.310)*
0.004 (-0.011, 0.019)
-0.007 (-0.029, 0.015)

-0.086 (-0.220, 0.049)

0.015 (-0.120, 0.151)

-0.012 (-0.044 0.020)
-0.012 (-0.040, 0.016)
0.032 (-0.000, 0.065)
0.013 (0.002, 0.025)*

-0.001 (-0.034, 0.031)
-0.023 (-0.051, 0.005)
0.005 (-0.027, 0.038)
0.005 (-0.007, 0.017)
-0.002 (-0.027, 0.023)

0.018 (-0.007, 0.043)

Notes: Values are adjusted mean (95% CI). *P , 0.05 versus baseline. Adjusted
model included changes from baseline in A1c and weight as covariates.
Abbreviations: ApoB, apolipoprotein B; ApoA1, apolipoprotein A1; LDL-C,
low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol;
VLDL-C, very low-density lipoprotein cholesterol; A1c, glycosylated hemoglobin;
Lp(a), lipoprotein(a); RLPs, remnant lipoproteins; ExQW, exenatide once weekly;
ExBID, exenatide twice daily.

of patients achieving lipoprotein normalization1–3 was 39%
for LDL cholesterol, 36% for triglycerides, 50% for VLDL
cholesterol, 42% for non-HDL cholesterol, and 20% for HDL
cholesterol. In the exenatide twice-daily treatment group,
the percentage of patients achieving lipoprotein normalization1–3 was 39% for triglycerides, 55% for VLDL cholesterol,
18% for non-HDL cholesterol, and 15% for HDL cholesterol.
During the 30-week assessment period, doses of lipid-lowering
agents remained generally stable in all patients in both treatment groups.
In the total cohort, both exenatide formulations reduced
high sensitivity C-reactive protein independent of glycemic
control and weight loss (P , 0.05; Figure 2F). Among the
patients with abnormal high sensitivity C-reactive protein at
baseline, high sensitivity C-reactive protein was significantly
reduced by 24% (P = 0.018). The percentages achieving high
sensitivity C-reactive protein normalization (,3 mg/L) were
33% with exenatide once weekly and 38% with exenatide
twice daily.

Vascular Health and Risk Management 2012:8

Discussion
Evidence garnered over the past two decades has revealed the
failure of standard lipoprotein measurements (eg, triglycerides,
total cholesterol, LDL cholesterol, and HDL cholesterol) to
identify many of the lipoprotein abnormalities contributing to
cardiovascular events.21 A recent meta-analysis of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B as markers
of cardiovascular disease demonstrated that apolipoprotein B
was the most reliable predictor of fatal or nonfatal ischemic
events.22 Across all studies analyzed, the mean apolipoprotein B
relative risk ratio was 12.0% greater than for LDL cholesterol
(P , 0.0001) and 5.7% higher than for non-HDL cholesterol (P , 0.001). These head-to-head analyses also rankordered the three markers as apolipoprotein B . non-HDL
cholesterol . LDL cholesterol. Over a 10-year period, an
apolipoprotein B strategy would prevent 500,000 more cardiovascular events than a non-HDL cholesterol strategy, and
a non-HDL cholesterol strategy would prevent 300,000 more
cardiovascular events than an LDL cholesterol strategy.22
Comprehensive lipoprotein testing, such as the vertical
auto profile, can better inform the clinician on the patient’s
underlying lipid disorders, above and beyond the standard
lipid panel, and can easily be incorporated into routine
clinical management. This potential benefit was demonstrated in a cohort of patients with type 2 diabetes from the
DURATION-1 exenatide clinical trial,16 in which there was a
preponderance of small, dense LDL cholesterol lipoproteins
(see Table 1) not apparent from the standard lipid panel.1–3 In
fact, the LDL cholesterol distribution in both treatment groups
(exenatide once weekly, exenatide twice daily) was skewed
towards the smaller LDL3 cholesterol and LDL4 cholesterol.
On average, the more buoyant HDL2 cholesterol was below
the recommended target goal1–3 at baseline, with a resulting
apolipoprotein B to apolipoprotein A1 ratio above 0.6 (60%).
Clearly, the most widely used clinical test failed to capture the
level of cardiovascular risk accurately in these patients.
Despite the appearance of a benign lipid profile at
baseline based on the standard lipid panel,1–3 a clinically
important shift in lipoprotein pattern away from small, dense
LDL4 cholesterol particles was observed with once-weekly
exenatide treatment. This is consistent with the reduction in
serum triglycerides that was also observed in patients treated
with exenatide once weekly. As triglyceride availability
in serum decreases, there is less cholesteryl ester transfer
protein-dependent loading of LDL cholesterol particles
with triglyceride. This, is turn, results in less hepatic lipasedependent lipolysis of LDL cholesterol particles, allowing
for them to remain larger, more buoyant, and possibly
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BL

Change from baseline for
apolipoprotiens (g/L) or ratio (%)

0.05

1.27

1.26

P = 0.053
0.025

0.023

1.22

1.24

0.85

B

0.85

−0.05

−0.04

*

Exenatide QW

−0.07

Exenatide BID

*

−0.15

−0.12

*

−0.20
−0.19

−0.25

C

ApoA1
(<1.45 g/L)

BL

3.0

3.0

*

ApoB
(>1.09 g/L)

0.95 0.94

ApoB/ApoA1
(>0.75)

0.36 0.37

0.65 0.65

0.28 0.28
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−0.10
−0.15
−0.20
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−0.35
−0.40
−0.45
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−0.55
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Figure 2 Effects of exenatide on apolipoproteins, lipoproteins, and high sensitivity C-reactive protein in the subgroup of patients with abnormal lipid values1–3 at baseline.
(A) Apolipoprotein A1, apolipoprotein B, and the ratio of these apolipoproteins; once weekly, n = 85, n = 9, and n = 22, respectively; twice daily, n = 78, 18, and 29, respectively.
(B) Low-density lipoprotein cholesterol and subclass ratios; once weekly, n = 28, 28, and 28, respectively; twice daily, n = 36, 36, and 36, respectively. (C) Triglycerides, very
low-density lipoprotein (VLDL) cholesterol, VLDL3 cholesterol, ratio of VLDL cholesterol/VLDL3 cholesterol, and intermediate-density lipoprotein cholesterol; once weekly,
n = 55, 18, 77, 106, and 7, respectively; twice daily, n = 52, 20, 75, 104, and 6, respectively. (D) Non-high-density lipoprotein cholesterol and remnant lipoproteins; once
weekly, n = 26 and n = 13, respectively; and twice daily, n = 34 and n = 21, respectively. (E) Total high-density lipoprotein cholesterol and its subclasses stratified by gender
and overall subclass ratio; once weekly, n = 51, 39, 57, 22, 47, and 95, respectively; twice daily, n = 46, 39, 55, 17, 44, and 96, respectively. (F) High sensitivity C-reactive
protein in the total cohort; once weekly, n = 104; twice daily, n = 103.
Notes: High sensitivity C-reactive protein in the subgroup with baseline . 3 mg/L and ,10 mg/L; once weekly, n = 41; twice daily, n = 32. Adjusted mean + standard error
of the mean. *Week 30 change from baseline P , 0.05.
Abbreviations: BL, baseline; ApoB, apolipoprotein B; ApoA1, apolipoprotein A1; LDL-C, low-density lipoprotein cholesterol; BID, twice daily; HDL-C, high-density
lipoprotein cholesterol; VLDL-C, very low-density lipoprotein cholesterol; IDL-C, intermediate-density lipoprotein cholesterol; RLPs, remnant lipoproteins; hsCRP, high
sensitivity C-reactive protein; QW, once weekly.
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less atherogenic. Exenatide once weekly also significantly
increased the levels of more buoyant HDL2 cholesterol particles, even after adjustment for treatment effects on HbA1c
and body weight. This shift suggests that HDL cholesterol
particles in exenatide-treated patients are maturing, and may
not be as vulnerable to lipolysis and catabolism by hepatic
lipase. Although the subject of debate, investigations have
suggested that the HDL2 cholesterol subtype may have a
greater cardioprotective effect in type 2 diabetes.23 Given
that the pathogenic potential of small dense LDL cholesterol
and apolipoprotein B may be further amplified by insulin
resistance and the hyperglycemia of type 2 diabetes, the
additional 4% reduction in apolipoprotein B, 1.6% reduction in HbA1c, and 4 kg weight loss observed with exenatide
therapy in this study would be expected to contribute to
overall risk reduction. Considering the changes in serum
levels of apolipoproteins, lipids, and lipoproteins observed in
this cohort, at a minimum, exenatide therapy was associated
with improvements in lipoprotein metabolism.
Hypertriglyceridemia is a marker of metabolic disease, and
is assuming an increasingly important role in the assessment and
management of cardiovascular disease risk.24 Prospective studies support a strong link between triglyceride concentrations
and cardiovascular risk in patients with type 2 diabetes, and
in individuals with lower levels of HDL and LDL cholesterol.
The incomplete hydrolysis of triglyceride-rich chylomicrons
and VLDL particles results in atherogenic cholesterol-enriched
remnant lipoproteins and elevated nonfasting triglycerides
that have been strongly correlated with high levels of remnant
lipoproteins. In our post hoc analysis, both exenatide formulations significantly reduced circulating concentrations of
triglycerides and VLDL cholesterol. The beneficial effects of
exenatide on the entire spectrum of apolipoproteins, lipoproteins, and lipoprotein subclasses were especially apparent in
patients with abnormal baseline values. Exenatide treatment
improved apolipoprotein B, LDL cholesterol, and several subclass risk indicators, including a number of other atherogenic
cholesterol-rich lipoproteins, triglycerides, and antiatherogenic
HDL cholesterol, HDL2 cholesterol, and HDL3 cholesterol.
Several previous studies offer additional insights
into the effects of exenatide on circulating lipids and
lipoproteins.10–12,25–29 In an open-label extension of the
first three Phase III exenatide twice daily clinical trials,
314 patients with type 2 diabetes treated with metformin
and/or sulfonylurea plus exenatide twice daily for 82 weeks
had significantly reduced triglycerides (−0.43 mmol/L) and
elevated HDL cholesterol (+0.12 mmol/L).25 There were
trends for reductions in total cholesterol, apolipoprotein B,
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and LDL cholesterol. By 3.5 years of twice-daily exenatide
treatment, the 151 evaluable patients had significant reductions
from baseline in triglycerides (−12%), total cholesterol (−5%),
and LDL cholesterol (−6%).26 In addition, HDL cholesterol
was significantly increased by 24%. Although the 25% of
patients who lost the most weight had the greatest improvements in triglycerides and HDL cholesterol, there was minimal
correlation between weight change and lipid improvements for
the total cohort. Correlations between HbA1c or fasting plasma
glucose and serum lipid concentrations were similarly low. In a
clinical practice setting, Bhushan et al10 reported a retrospective
analysis of the laboratory and medical records of 176 adults
with both type 2 diabetes and metabolic syndrome treated
with exenatide twice daily for 16 weeks. Exenatide significantly reduced total cholesterol and LDL cholesterol, but not
triglycerides. Of interest, these results were not attributable to
changes in concomitant dyslipidemia medications. In a later
clinical trial, Bunck et al11 evaluated 69 patients with type 2
diabetes treated chronically with metformin and exenatide
twice daily or insulin glargine for a year. Compared with
insulin, exenatide twice daily significantly reduced post-meal
excursions in triglycerides, apolipoprotein B48, VLDL cholesterol, and free fatty acids, and increased HDL cholesterol.
Finally, acute exenatide administration suppressed postprandial excursions of proatherogenic lipoproteins in overweight/
obese adults with impaired glucose tolerance or recent onset
type 2 diabetes (57% treated with statins).12,27 One injection of exenatide markedly reduced postprandial elevation
of triglycerides, apolipoprotein B-48, apolipoprotein CIII,
remnant lipoprotein cholesterol, and remnant lipoprotein
triglyceride (each P , 0.05 versus placebo). A subgroup
analysis found that postprandial endothelial function was
higher after exenatide than after placebo (P = 0.0002) and
that exenatide-induced changes in postprandial triglyceride
concentrations explained 64% of this effect. Further, the effects
of exenatide on postprandial lipoproteins were not affected
by the degree of loss of glucose control nor by dyslipidemia
treatment with statins. In the DURATION-2 study, patients
with type 2 diabetes suboptimally controlled with metformin
and treated with exenatide once weekly for 26 weeks had
significantly increased HDL cholesterol compared with
baseline (P , 0.05),28 and this improvement was maintained
out to 52 weeks.29 Taken together, these data lend further support to a role for exenatide in improving the typical diabetic
proatherogenic profile that is at least partially independent of
the effects of exenatide on glycemic control and weight loss.
Although little is known concerning potential mechanisms to
explain the effects of exenatide on lipoproteins, in a recent

submit your manuscript | www.dovepress.com

Dovepress

627

Dovepress

Chiquette et al

study, exenatide acutely suppressed intestinal lipoprotein
production, possibly through a direct effect on intestinal
lipoprotein production, but independent of changes in body
weight, satiety, gastric emptying, glucagon, and circulating
free fatty acid concentrations.30
The interplay between proinflammatory cytokines and
lipid homeostasis has been well described.31 Type 2 diabetes
is associated with a chronically heightened level of systemic
inflammation characterized by increased plasma levels of
numerous inflammatory biomarkers, including high sensitivity
C-reactive protein. In a large, representative study, the relationship between circulating levels of high sensitivity C-reactive
protein and cardiovascular disease mortality was tracked over
7 years.32 In these patients, individuals with a baseline high
sensitivity C-reactive protein . 3 mg/L were significantly
more likely to die from cardiovascular disease (about 1.5fold) than were individuals with high sensitivity C-reactive
protein # 3 mg/L (P , 0.004). Furthermore, this association
remained even after adjustment for age, gender, total cholesterol,
HDL cholesterol, triglycerides, diabetes duration, HbA1c, hypertension, smoking, residence area, and body mass index, and was
independent of pre-existing myocardial infarction events.
Exenatide treatment was observed to reduce high sensitivity
C-reactive protein significantly, independent of glycemic control and weight loss in the total lipid-analysis cohort. When
patients with type 2 diabetes suboptimally controlled with
metformin and/or sulfonylurea were treated with exenatide
twice daily for 16 weeks, high sensitivity C-reactive protein
was significantly reduced (from 0.4 ± 0.5 to 0.2 ± 0.3 mg/L)
compared with placebo (increased from 0.6 ± 0.4 to
1.4 ± 1.6 mg/L; P , 0.05).33 In the DURATION-2 study,
patients whose type 2 diabetes was suboptimally controlled
with metformin and who were treated with exenatide once
weekly for 26 weeks had significantly reduced high sensitivity C-reactive protein (P , 0.05),28 and this improvement
reached −25% by week 52.29
The limitations of this study include the post hoc nature
of the analysis, the small number of patients, especially those
with abnormal baseline values, and the open-label treatment
design. Furthermore, these analyses were exploratory in
nature, and the results should be considered primarily as
hypothesis generating.

Conclusion
This post hoc analysis demonstrated that exenatide therapy
may improve a wide spectrum of cardiovascular disease risk
markers. Continuous exenatide exposure with once-weekly
administration elicited a greater response than exenatide
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twice daily. Importantly, these improvements were at least
partially mediated through mechanisms distinct from the
effects of exenatide on hyperglycemia and obesity. Thus,
administration of once-weekly exenatide has the potential
to modify cardiovascular disease risk factors beneficially
in patients with type 2 diabetes and, thus, warrants further
clinical investigation in prospective studies. An ongoing, prospective morbidity and mortality outcomes study (EXSCEL,
clinicaltrials.gov NCT01144338) is expected to elucidate
further the potential cardiovascular benefits stemming from
the effect of exenatide once weekly on dyslipidemia.
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